These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34065399)

  • 1. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.
    Capuano C; Pighi C; Battella S; De Federicis D; Galandrini R; Palmieri G
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.
    Capuano C; Pighi C; Molfetta R; Paolini R; Battella S; Palmieri G; Giannini G; Belardinilli F; Santoni A; Galandrini R
    Oncoimmunology; 2017; 6(3):e1290037. PubMed ID: 28405525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Targeting Anti-CD20 Antibodies Mediate
    Capuano C; Battella S; Pighi C; Franchitti L; Turriziani O; Morrone S; Santoni A; Galandrini R; Palmieri G
    Front Immunol; 2018; 9():1031. PubMed ID: 29867997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
    Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
    Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
    Battella S; Cox MC; Santoni A; Palmieri G
    J Leukoc Biol; 2016 Jan; 99(1):87-96. PubMed ID: 26136506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immune therapies to enhance anti-tumor responses by NK cells.
    Mentlik James A; Cohen AD; Campbell KS
    Front Immunol; 2013 Dec; 4():481. PubMed ID: 24391651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells.
    Dixon KJ; Wu J; Walcheck B
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Human Natural Killer Cells Antibody-dependent Cellular Cytotoxicity (ADCC) Using Plate-bound Anti-CD16 Antibodies.
    Liu W
    Bio Protoc; 2022 Jan; 12(1):e4285. PubMed ID: 35118176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen).
    Lanier LL; Kipps TJ; Phillips JH
    J Exp Med; 1985 Dec; 162(6):2089-106. PubMed ID: 2415663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.
    Bernard NF; Kiani Z; Tremblay-McLean A; Kant SA; Leeks CE; Dupuy FP
    Front Immunol; 2017; 8():1033. PubMed ID: 28883824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.
    Moretta A; Bottino C; Pende D; Tripodi G; Tambussi G; Viale O; Orengo A; Barbaresi M; Merli A; Ciccone E
    J Exp Med; 1990 Dec; 172(6):1589-98. PubMed ID: 2147946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies.
    Galatiuc C; Gherman M; Metes D; Sulica A; DeLeo A; Whiteside TL; Herberman RB
    Cell Immunol; 1995 Jul; 163(2):167-77. PubMed ID: 7606790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
    Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
    Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.
    Lo Nigro C; Macagno M; Sangiolo D; Bertolaccini L; Aglietta M; Merlano MC
    Ann Transl Med; 2019 Mar; 7(5):105. PubMed ID: 31019955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.
    Bowles JA; Weiner GJ
    J Immunol Methods; 2005 Sep; 304(1-2):88-99. PubMed ID: 16109421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.